PharmiWeb.com - Global Pharma News & Resources

Press Releases

Date Title Company
31-May-2020 (ASCO2020) Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates, Showing Promising Clinical Effects with Combination Therapies Ascentage Pharma
31-May-2020 (ASCO2020) Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates, Showing Promising Clinical Effects with Combination Therapies Ascentage Pharma
30-May-2020 MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients MimiVax LLC
30-May-2020 Guardant360 test results may provide prognostic information beyond the detection of actionable biomarkers for ALK-rearranged NSCLC patients Guardant Health AMEA
30-May-2020 Coronavirus (COVID-19) Update: Daily Roundup U.S. Food and Drug Administration
30-May-2020 Coronavirus (COVID-19) Update: Daily Roundup U.S. Food and Drug Administration
29-May-2020 Varian to Participate in Goldman Sachs Global Virtual Healthcare Conference Varian
29-May-2020 Mylan Invalidates Sanofi's Lantus® SoloSTAR® Device Patents in IPR Proceedings Mylan N.V.
29-May-2020 Arcadia Emphasises the Role of Custom Software Development in Global Medical Safety Arcadia Inc
29-May-2020 Chi-Med Announces NDA Acceptance in China for Savolitinib in the Treatment of Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations Chi-Med
29-May-2020 New number of shares and votes in Moberg Pharma AB (publ) Moberg Pharma
29-May-2020 Santhera Provides Update on the Ongoing Regulatory Review of Puldysa® (Idebenone) by the CHMP in Duchenne Muscular Dystrophy (DMD) Santhera Pharmaceuticals
29-May-2020 Interim analysis presented at the American Society of Clinical Oncology (ASCO) Annual Meeting London’s Global University
29-May-2020 COVID-19 vaccine development: new guidelines for ethical approach to infecting trial volunteers University of Warwick
29-May-2020 First patient dosed in Achilles’ Phase I/II study in melanoma Syncona
29-May-2020 Immunotherapy Drugs Market Worth $274.6 Billion by 2025 - Exclusive Report by MarketsandMarkets™ MarketsandMarkets
29-May-2020 Development of Drug Resistance in Colon Cancer Patients Contributed to Failure of Oxaliplatin-based HIPEC PRODIGE 7 Trial Nagourney Cancer Institute
29-May-2020 Medios AG: Medios AG moves to the Prime Standard stock exchange segment Medios AG
29-May-2020 Immunic, Inc. to Participate in Investor and Industry Conferences in June Immunic, Inc.
29-May-2020 Resumption of air traffic at Rostock-Laage airport: CENTOGENE AG tests airport employees for the SARS-CoV-2-virus CENTOGENE AG